Nkarta (NASDAQ:NKTX) Issues Quarterly Earnings Results

Nkarta (NASDAQ:NKTX) issued its quarterly earnings data on Monday. The company reported ($0.29) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.32) by $0.03, Zacks reports.

Nkarta Stock Performance

NKTX stock remained flat at $1.96 on Monday. The company had a trading volume of 513,551 shares, compared to its average volume of 935,677. The stock’s 50-day simple moving average is $2.14 and its 200 day simple moving average is $2.02. Nkarta has a 1 year low of $1.31 and a 1 year high of $3.81. The firm has a market capitalization of $139.22 million, a PE ratio of -1.32 and a beta of 0.86.

Institutional Trading of Nkarta

Institutional investors have recently bought and sold shares of the stock. Geode Capital Management LLC increased its holdings in shares of Nkarta by 0.8% during the 2nd quarter. Geode Capital Management LLC now owns 1,208,378 shares of the company’s stock valued at $2,006,000 after purchasing an additional 10,065 shares in the last quarter. Goldman Sachs Group Inc. grew its position in Nkarta by 13.3% during the first quarter. Goldman Sachs Group Inc. now owns 681,068 shares of the company’s stock valued at $1,253,000 after buying an additional 80,211 shares during the period. AQR Capital Management LLC increased its holdings in Nkarta by 300.5% in the first quarter. AQR Capital Management LLC now owns 672,078 shares of the company’s stock valued at $1,237,000 after buying an additional 504,272 shares in the last quarter. BNP Paribas Financial Markets increased its holdings in Nkarta by 4.0% in the second quarter. BNP Paribas Financial Markets now owns 231,081 shares of the company’s stock valued at $384,000 after buying an additional 8,968 shares in the last quarter. Finally, Jane Street Group LLC raised its position in shares of Nkarta by 118.7% in the first quarter. Jane Street Group LLC now owns 134,286 shares of the company’s stock worth $247,000 after acquiring an additional 852,559 shares during the period. 80.54% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on NKTX. Needham & Company LLC restated a “buy” rating and issued a $10.00 target price on shares of Nkarta in a report on Wednesday, August 13th. Stifel Nicolaus decreased their price objective on shares of Nkarta from $14.00 to $12.00 and set a “buy” rating for the company in a research note on Thursday, August 14th. Weiss Ratings reissued a “sell (d-)” rating on shares of Nkarta in a research note on Friday, October 31st. Finally, Wall Street Zen raised shares of Nkarta from a “sell” rating to a “hold” rating in a research note on Saturday, October 25th. Four investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $13.50.

Nkarta Company Profile

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.